Recently, Tianjin Pharma received the Notice of Approval for Marketing Application of API for famotidine, approved and issued by National Medical Products Administration.

It is understood that famotidine is a guanidinazole H2 receptor blocker with high affinity for H2 receptors. It can not only effectively inhibit basal gastric acid, nocturnal gastric acid and gastric acid secretion caused by food stimulation, but also can inhibit the secretion of pepsin. Currently, the dosage forms on the market mainly include tablets, injections, capsules, granules, etc. Among them, famotidine injection has been marketed domestically and internationally, and is mainly suitable for upper gastrointestinal hemorrhage caused by peptic ulcer disease, gastric and duodenal mucosa erosion and bleeding caused by various reasons other than tumors and varicose veins of the esophagus and gastric fundus.

 The marketing approval of famotidine API will further enrich the Company's product structure, give full play to the advantages of integration of raw materials and preparations, and help expand the Company's business scope.